Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Weight loss injections work by regulating your appetite by mimicking a naturally produced hormone called glucagon-like ...

Losing weight after a years-long struggle, this letter writer gave credit to the method — then came the judgmental comments.

A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the drugs’ ability to ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

California would scale back state Medicaid coverage for immigrants without legal status, eliminate coverage for certain ...

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.